Photo taken from Paolo Tarantino/Twitter
Nov 19, 2023, 17:20
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:
“Capivasertib is now approved in combo with fulvestrant for pts with pretreated ER+/HER2- MBC whose tumor has an alteration in PIK3CA, AKT1 or PTEN (approx 40%).
More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i.”
For more information click here.
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19